This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
CorMedix (CRMD) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
CorMedix (CRMD) delivered earnings and revenue surprises of -9.09% and -73.08%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
CorMedix (CRMD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
CorMedix (CRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CorMedix (CRMD) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
CorMedix (CRMD) delivered earnings and revenue surprises of 24.14% and 173.33%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Will CorMedix (CRMD) Report Negative Q4 Earnings? What You Should Know
by Zacks Equity Research
CorMedix (CRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Options Traders Expect Huge Moves in CorMedix (CRMD) Stock
by Zacks Equity Research
Investors need to pay close attention to CorMedix (CRMD) stock based on the movements in the options market lately.
Implied Volatility Surging for CorMedix (CRMD) Stock Options
by Zacks Equity Research
Investors need to pay close attention to CorMedix (CRMD) stock based on the movements in the options market lately.
CorMedix (CRMD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
CorMedix (CRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Top Sectors of July & Their Top Stocks
by Sanghamitra Saha
Inside the top sectors of July and their top-performing stocks.
Are Options Traders Betting on a Big Move in CorMedix (CRMD) Stock?
by Zacks Equity Research
Investors in CorMedix (CRMD) need to pay close attention to the stock based on moves in the options market lately.
Is the Options Market Predicting a Spike in CorMedix (CRMD) Stock?
by Zacks Equity Research
Investors in CorMedix (CRMD) need to pay close attention to the stock based on moves in the options market lately.
Implied Volatility Surging For CorMedix Inc (CRMD) Stock Options
by Zacks Equity Research
CorMedix Inc (CRMD) Stock looks to be lucrative to the option traders on the back of its surging implied volatility.
Implied Volatility Surging for CorMedix (CRMD) Stock Options
by Zacks Equity Research
CorMedix (CRMD) warrants investors' attention based on moves in the options market lately.
Implied Volatility Surging for CorMedix (CRMD) Stock Options
by Zacks Equity Research
Investors need to pay close attention to CorMedix (CRMD) stock based on the movements in the options market lately.
Implied Volatility Surging for CorMedix (CRMD) Stock Options
by Zacks Equity Research
Investors in CorMedix, Inc. (CRMD) need to pay close attention to the stock based on moves in the options market lately.
Are Options Traders Betting on a Big Move in CorMedix (CRMD) Stock?
by Zacks Equity Research
Investors in CorMedix, Inc. (CRMD) need to pay close attention to the stock based on moves in the options market lately.
Is the Options Market Predicting a Spike in CorMedix (CRMD) Stock?
by Zacks Equity Research
Investors in CorMedix, Inc. (CRMD) need to pay close attention to the stock based on moves in the options market lately.